Plasmology4

Plasmology4 is a private Arizona-based plasma medicine company developing non-thermal plasma technology for healthcare applications. Its core platform, Plaz4, is being advanced through the Plaz4 1000 system, a medical device intended to reduce microbial burden in wounds while supporting wound healing without drugs. The company is primarily focused on infected and chronic wounds, including wounds involving multidrug-resistant organisms such as MRSA. Its lead product has received FDA Breakthrough Device designation for treatment of multidrug-refractory bacterial and/or fungal pathogen bioburden in a wound bed, but the product is not yet FDA approved or commercially available. Plasmology4 positions itself as a platform company with a patent-backed non-thermal plasma technology that may have broader future applications across human healthcare.